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Background. To investigate clinical variables such as gestational age, sex, weight, the
therapeutic regimens used and mechanical ventilation that might affect morphine requirements
and plasma concentrations of morphine and its metabolites.
Methods. In a double-blind study, neonates and infants strati®ed for age [group I 0±4 weeks
(neonates), group II >4±26 weeks, group III >26±52 weeks, group IV >1±3 yr] admitted to
the paediatric intensive care unit after abdominal or thoracic surgery received morphine 100
mg kg±1 after surgery, and were randomly assigned to either continuous morphine 10 mg kg±1
h±1 or intermittent morphine boluses 30 mg kg±1 every 3 h. Pain was measured using the
COMFORT behavioural scale and a visual analogue scale. Additional morphine was
administered on guidance of the pain scores. Morphine, morphine-3-glucuronide (M3G) and
morphine-6-glucuronide (M6G) plasma concentrations were measured before, directly after,
and at 6, 12 and 24 h after surgery.
Results. Multiple regression analysis of different variables revealed that age was the most
important factor affecting morphine requirements and plasma morphine concentrations.
Signi®cantly fewer neonates required additional morphine doses compared with all other age
groups (P<0.001). Method of morphine administration (intermittent vs continuous) had no
signi®cant in¯uence on morphine requirements. Neonates had signi®cantly higher plasma
concentrations of morphine, M3G and M6G (all P<0.001), and signi®cantly lower
M6G/morphine ratio (P<0.03) than the older children. The M6G/M3G ratio was similar in all
age groups.
Conclusions. Neonates have a narrower therapeutic window for postoperative morphine
analgesia than older age groups, with no difference in the safety or effectiveness of intermittent
doses compared with continuous infusions in any of these age groups. In infants >1 month of
age, analgesia is achieved after morphine infusions ranging from 10.9 to 12.3 mg kg±1 h±1 at
plasma concentrations of <15 ng ml±1.
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Morphine is the most frequently used agent for post-
operative analgesia in neonates, infants and children.1±5
Therapeutic plasma concentrations of morphine depend on
factors such as route of administration, total body clearance
and volume of distribution. These are affected by the age,
hepatic function, renal function and clinical condition.6±9 As
a result of these factors, studies of morphine pharmaco-
kinetics report a noticeable variability between patients.10
While preterm neonates are regarded as a separate group
with regard to serum half-life and morphine clearance, the
distinction between term newborns and older infants is less
clearly de®ned.10 In addition, the pharmacodynamics of
morphine may change rapidly during infancy, being in¯u-
enced by sex,11 the maturation of opioid receptors,12±14
earlier experiences of pain,15 as well as social and cultural
factors.16
Despite the reported variability, most previous studies
have investigated the effects of morphine only in 4±20
patients within the different age groups,10 thus precluding
their ability to examine the effects of underlying clinical and
demographic factors.
We designed a prospective study including larger num-
bers of patients in each age group, enabling us to elucidate
the impact of various clinical and demographic variables on
both morphine requirements and morphine pharmaco-
kinetics. We have recently reported the effects of morphine
administration on hormonal and metabolic stress responses
following major surgery in the same patient population.17
Methods
After approval from the Medical Ethics Committee for the
Erasmus MC, Rotterdam, written consent was obtained
from all parents. We included 204 children aged 0±3 yr
admitted to the paediatric surgical intensive care unit
following non-cardiac thoracic and abdominal surgery.
Patients were excluded if they had received morphine <6 h
before surgery, or suffered from hepatic, renal or neuro-
logical disorders. Patients were strati®ed into four age
groups: group I 0±4 weeks, group II 4±26 weeks, group III
26±52 weeks, group IV 1±3 yr. They were randomly
assigned to receive either i.v. continuous morphine (CM) or
intermittent morphine (IM). The pharmacist prepared all
study drugs and strata-speci®c schedules for randomization.
For each age group, the boxes containing the study drugs
were numbered consecutively and used in sequence. Each
patient received a study number consisting of a number of
the age group (I±IV) and a sequence number (1±68).
Anaesthetic management was standardized in all patients.
Anaesthesia was induced with i.v. thiopental 3±5 mg kg±1
or, when i.v. induction was impossible, by inhalation of
halothane in oxygen (<5% of patients). After the insertion of
an i.v. line, the anaesthetic procedure was similar for all
patients. Fentanyl 5 mg kg±1 was given before orotracheal
intubation, which was facilitated with atracurium 0.5±1 mg
kg±1 or succinylcholine 2 mg kg±1. Ventilation was
controlled and anaesthesia was maintained with iso¯urane
0.5 minimum alveolar concentration in nitrous oxide 60% in
oxygen or air in oxygen. Perioperative ¯uids were
standardized to maintain a glucose infusion rate of 4±6
mg kg±1 min±1. Body temperature was kept within normal
ranges. A peripheral artery was cannulated and the meas-
ured mean arterial pressure (MAP) and heart rate (HR) data
served as preoperative baseline data. Patients received a
second dose of fentanyl 5 mg kg±1 before surgical incision
and additional doses of fentanyl 2 mg kg±1 when HR and/or
MAP were 15% above the baseline values. At the end of
surgery, the neuromuscular block was antagonized and the
tracheal tube removed. Mechanical ventilation was con-
tinued in patients who required ventilatory assistance after
surgery.
The anaesthetist and the surgeon then jointly computed
the surgical stress score (SSS).18 This measure takes into
account seven items: amount of blood loss, site of surgery,
amount of super®cial trauma, extent of visceral trauma,
duration of surgery, associated stress factors (hypothermia,
localized or generalized infection, and prematurity) and
cardiac surgery. The total scores in this study (excluding
cardiac surgery and prematurity <35 weeks) could range
from 3 to 24.
Directly after surgery, all patients received an i.v. loading
dose of morphine hydrochloride 100 mg kg±1 in 2 min. For
children in the CM group this was followed by a morphine
infusion 10 mg kg±1 h±1, combined with 3-hourly i.v.
placebo (saline) boluses. Children in the IM group received
3-hourly i.v. morphine 30 mg kg±1, combined with a
continuous placebo infusion (saline). The amount of glucose
and the volume of ¯uid was the same in both treatment
groups. The clinical staff were blinded to the study group
allocation until data collection was complete. The continu-
ous infusion was started within 30 min after the loading
dose; the ®rst intermittent bolus (morphine or placebo) was
given 3 h after surgery.
Pain was assessed by nurses trained in the use of the
behavioural part of the COMFORT scale (CS),19 20 the total
score of which can range from 6 to 30, and a 0±10 visual
analogue scale (VAS). The modi®ed CS counts six
behavioural items: alertness, calmness, respiratory response
(for mechanically ventilated children) or crying (for non-
ventilated children), movement, muscle tone and facial
tension.20 VAS scores were taken after the 2-min observa-
tion periods needed for the CS. Additional analgesia was
given when there were signs of pain, indicated by VAS
score >4. During the ®rst hour after surgery, one-third of
the loading dose of morphine could be repeated every
15 min, and thereafter morphine 5 mg kg±1 every 10 min if
required. Nursing interventions included pain assessment,
blood sampling and administration of intermittent bolus
(placebo or morphine) medication, and then nursing as
needed. No other analgesic or sedative drugs were used.
Arterial blood samples were taken after induction of
anaesthesia (baseline), at the end of surgery, and at 6, 12,
Morphine therapy in postoperative infants
643
and 24 h after surgery for measurement of blood gas values
and plasma concentrations of morphine, morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G).
Respiratory depression was de®ned by the presence of
apnoea or arterial PaCO2 >7.3 kPa in spontaneously
breathing patients.21 Blood samples were taken at time
points corresponding with trough plasma morphine concen-
trations in the IM group.
Morphine and metabolite assay
The blood samples (1.4 ml) were centrifuged at 3000 rpm
for 10 min and the serum was stored at ±20°C until analysis.
Serum aliquots (0.6 ml) were extracted with the Baker-10
extraction system (Baker Chemicals, Deventer, the
Netherlands) ®tted with 1-ml disposable cyclohexyl cart-
ridges (Baker, Chemicals, Deventer, the Netherlands). The
extraction column was conditioned with two column
volumes methanol, two column volumes water and
diammonium sulphate 1 ml 500 mM, pH 9.3. The serum
(0.6 ml) was diluted with diammonium sulphate 0.6 ml
500 mM, pH 9.3 before being introduced into the extraction
column. It was washed with diammonium sulphate 2 ml
50 mM, pH 9.3, after which it was allowed to dry for 15 s.
The elution was carried out with KH2PO4 buffer 0.5 ml
0.01 M, pH 2.1 containing acetonitrile 11%. From this elute
50 ml was injected onto the analytical column.
The HPLC system comprised a Spectro¯ow 400 solvent
delivery system (Kratos, Rotterdam, the Netherlands)
equipped with a degasser (Separations, HI-Ambacht, the
Netherlands), a Marathon auto sampler (Separations, HI-
Ambacht, the Netherlands), a Spectro¯ow 773 UV detector
at l=210 nm (Separations, HI-Ambacht, the Netherlands),
in sequence with an ESA electrochemical detector (ESA,
Kratos, Rotterdam, the Netherlands) equipped with an
analytical cell (Model 5010). All compounds leave the UV
detector chemically intact and so the electrochemically
active components can be oxidized in the electrochemical
cell. This type of electrochemical cell contains two separate
analytical cells, which makes it possible to create a small
window of applied potential. The detector 2 potential was
set at 0.4 V, while the detector 1 potential was 0.3 V. This
minimizes interfering peaks because only compounds with
an oxidation potential of 0.3±0.4 V are recorded.
Chromatographic separations were achieved using a Cp-
Sper C8 column (25034.6 mm) (Chrompack, Bergen op
Zoom, the Netherlands). The mobile phase was KH2PO4
buffer 0.01 M, pH 2.1 containing acetonitrile 11% and
heptane sulphonic acid 0.4 g litre±1.
For the measurement of M3G, M6G and morphine,
calibration samples contained all three compounds. In
serum, all three calibration graphs (six data points) were
linear in the concentration ranges 25±580 ng ml±1
(r=0.9992) for M3G, 5±100 ng ml±1 (r=0.9982) for M6G
and 5±90 ng ml±1 (r=0.9963) for morphine. The quanti®-
cation limit was 5 ng ml±1 for morphine and M6G and 25 ng
ml±1 for M3G. However, in individual samples, the
chromatogram allowed for a lower threshold. As we used
median values in this study, these are not affected by the
values under the detection limit. In this concentration range,
the intra- and inter-day precision was less than 10% for all
compounds and the accuracy was about 5% (Table 1).22 23
Standardized automated laboratory analysers were used to
measure plasma concentrations of bilirubin and creatinine.
Table 1 Intra-day (n=5) and inter-day (n=8) coef®cients of variation (% CV) of spiked morphine and its metabolites in human serum in vitro. Accuracy is
the ability to measure the quantity of the compound being determined. Precision: a method is precise if it yields the same results for a series of replicate
determinations
Compound Concentration added Concentration measured Precision Accuracy
(ng ml±1) (ng ml±1) (% CV) (%)
Intra-day M3G 574 561 1.8 2.3
306 293 3.1 4.2
158 161 1.9 1.9
M6G 203 195 3.1 3.9
108 101 5.0 6.5
56 54 3.7 3.6
Morphine 159 154 5.2 3.1
85 80 6.3 5.9
44 42 4.8 4.5
Inter-day M3G 574 564 2.5 1.7
306 299 3.4 2.3
158 162 2.2 2.5
M6G 203 201 3.7 1.0
108 105 5.4 2.8
56 56 5.4 0.0
Morphine 159 156 4.4 1.9
85 81 5.4 4.7
44 43 3.9 2.3
M3G=morphine-3-glucuronide, M6G=morphine-6-glucuronide.
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Statistical analysis
Relations between age and plasma concentrations of
morphine, M3G and M6G were investigated using ANOVA.
We applied multiple regression analysis to determine the
effects of the gestational age, sex, birth weight, study
weight, preoperative and postoperative mechanical venti-
lation, preoperative plasma concentrations of creatinine and
total bilirubin, SSS, location of surgery, morphine treatment
and a history of previous surgery, in addition to age on
morphine requirements and plasma concentrations of mor-
phine and its metabolites. In all analyses, the morphine and
metabolite plasma concentrations were transformed loga-
rithmically in order to approximate normal distribution.
Relations between the various factors and the need (yes/no)
for extra morphine were assessed by logistic regression
analysis.
All 204 patients were included in an intention-to-treat
analysis. Seven had to be excluded from morphine data
analysis (4 in CM, 3 in IM): ®ve had detectable morphine
plasma concentrations at baseline as a result of previous
morphine administration (congenital diaphragmatic hernia,
n=4; meconium peritonitis, n=1), one patient died within 3 h
after surgery (vessel loop and therapy-resistant pulmonary
hypertension), and another patient required neuromuscular
blockade after surgery (hemi-hepatectomy). Logistic and
laboratory problems resulted in missing data for several of
the 197 included patients. Spearman's rho was used for
correlation coef®cients and the other statistical tests used
are given in the text. To control the a-error for the multiple
statistical tests performed, the level of signi®cance was set
at P=0.01, instead of the conventional P=0.05. The power
analysis for the comparative randomized trial was given in
the original article.17 In the present paper the effects of age
and various other factors are investigated with respect to
morphine requirements and plasma concentrations. With a
study group of 200 infants, correlations as small as r=0.25
are detectable (a=0.01) with a power greater than 80%.
Results
Table 2 gives the clinical and surgical characteristics of the
197 enrolled patients, strati®ed by age group and rando-
mized treatment group (97 in the CM group and 100 in the
IM group).
Patient characteristics and clinical variables within the
four age groups were similar in the two randomized groups.
Although the surgical procedures varied, the age and
treatment groups had similar SSS.
Table 2 Patient data and details of surgery in the four ages groups (I 0±4 weeks, II >4±26 weeks, III >26±52 weeks, IV >1±3 yr). Data are mean (SD)
unless stated otherwise
Group I Group II Group III Group IV
CM IM CM IM CM IM CM IM
(n=31) (n=32) (n=32) (n=33) (n=16) (n=14) (n=18) (n=21)
Median age (days)
(range)
4 (0±28) 2 (0±17) 90 (29±173) 95 (30±179) 273 (185±351) 267 (187±330) 613 (368±1070) 574 (393±1067)
Study weight (kg) 3.2 (0.7) 2.9 (0.5) 5.0 (1.5) 4.7 (1.8) 6.9 (1.6) 7.3 (1.3) 11.1 (1.9) 11.1 (2.5)
Birth weight (kg) 3.1 (0.7) 2.9 (0.5) 2.9 (1.2) 2.7 (1.2) 2.7 (0.9) 2.6 (1.0) 2.7 (0.7) 3.1 (0.9)
Gestational age
(weeks)
38 (3) 38 (2) 37 (4) 37 (5) 37 (5) 37 (5) 38 (2) 38 (3)
Boys/girls (n) 19/12 18/14 20/12 22/11 9/7 9/5 9/9 9/12
Plasma creatinine
concentration (mmol
litre±1)
46 (22) 47 (25) 26 (18) 23 (14) 31 (36) 54 (45) 28 (36) 27 (16)
Plasma total bilirubin
(mmol litre±1)
91 (67) 108 (56) 23 (39) 35 (55) 15 (31) 7 (3) 6 (2) 7 (3)
Plasma bilirubin
glucuronide
concentration (mmol
litre±1)
6 (4) 9 (8) 14 (26) 23 (42) 12 (32) 2 (1) 3 (1) 3 (1)
Mechanical
ventilation before
surgery (n)
10 5 3 0 0 0 0 0
Mechanical
ventilation >24 h after
surgery (n)
22 14 4 7 0 1 2 2
Surgical stress score 9.8 (2.9) 9.7 (2.8) 9.3 (3.3) 9.6 (2.5) 8.4 (3.1) 10.0 (2.8) 10.6 (2.9) 9.8 (3.5)
Surgery (n)
Thoracic 1 8 6 4 0 2 5 1
Thoracic
combined with
abdominal
0 2 0 0 0 0 3 2
Abdominal high/low 19/11 7/13 6/19 8/19 8/8 3/9 6/2 5/9
Super®cial 0 2 1 2 0 0 2 4
CM=continuous morphine, IM=intermittent morphine.
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Overall, there were signi®cant differences in the use of
extra morphine between the age groups (P<0.001), but not
between the treatment groups.
Table 3 shows the need for extra morphine and the total
requirement for morphine (excluding the loading dose) in
the four age groups. Only 38% of neonates (group I)
required additional morphine, a signi®cantly lower percent-
age than in all older age groups. Signi®cantly more infants
aged 4±26 weeks required additional morphine than the
children aged 1±3 yr.
Multiple logistic regression analysis of all variables
showed that age group, plasma concentrations of total
bilirubin and the SSS were the most important factors
affecting the need for additional morphine. The percentage
of patients needing extra morphine was signi®cantly higher
in group II than in group I (91% vs 38%, P<0.001). In all
age groups, increases in plasma bilirubin concentrations
reduced the need for extra morphine (P=0.01) whereas a
higher SSS increased the need for extra morphine
(P=0.007).
During the ®rst hour after the loading dose, the need for
additional morphine was only related to age. A signi®cantly
higher percentage of patients in group II than in group I
(P=0.01) needed extra morphine in this period. There was
no consistency in the need for extra morphine during the
®rst hour after surgery and/or between the other time
periods (1±6, >6±12, >12±18 and >18±24 h after surgery).
Figure 1 shows the percentage of patients needing additional
morphine during each of these periods.
The age of the child and type of morphine administration
signi®cantly affected the morphine dosage (kg±1 day±1)
required. However, inherent to the protocol design, the
dosage in the CM group was always 30 mg kg±1 higher than
in the IM group. Disregarding this in the CM group, there
was no difference between the groups. Group I needed
signi®cantly less morphine than the other age groups
(ANOVA, P<0.001) (Table 3).
Analysis of morphine plasma concentrations 6 h after
surgery revealed a signi®cant difference between age
groups depending on the type of morphine administration.
Therefore, the effect of age groups was evaluated within the
treatment groups separately. Plasma concentrations at 12
and 24 h after surgery were no longer dependent on type of
treatment.
Table 4 gives the plasma concentrations of morphine and
its metabolites M3G and M6G, and the differences between
age and treatment groups at 6, 12 and 24 h after surgery.
Plasma concentrations were signi®cantly higher in group I
than in the other groups, and in group II vs group IV
(Table 4). ANOVA showed that morphine plasma concentra-
tions were signi®cantly affected by the total morphine dose
administered (P<0.001). Plasma morphine concentrations in
the CM neonatal group (at 12 and 24 h after surgery) were
signi®cantly correlated with plasma creatinine concentra-
tions (r=0.5, P=0.01; r=0.4, P=0.04, respectively), and with
plasma bilirubin concentrations (both r=0.6, P=0.001).
Dif®culties in detection of M3G plasma concentrations in
the neonatal group (interfering spikes) resulted in many
missing values for M3G in this group (n=32). ANOVA of
M3G and M6G plasma concentrations revealed that the age
group and the administered dosage of morphine signi®-
cantly affected these plasma concentrations (both P<0.001).
Although plasma concentrations of M3G and M6G were
higher after CM than after IM, this difference was only
signi®cant for M3G at 6 h after surgery. M3G and M6G
plasma concentrations were signi®cantly higher in group I
than in the other groups, and in group II vs group IV at 12
and 24 h after surgery (all P<0.001) (Table 4). M6G plasma
concentrations correlated signi®cantly with plasma creati-
nine only in the neonates, and only in CM at 12 and 24 h
after surgery (r=0.5, P=0.01 and r=0.5, P=0.002, respect-
ively). No such correlation was found for M3G.
Figure 2 shows the median plasma concentrations of
morphine, M3G and M6G in the four age groups for CM and
Table 3 Morphine requirements up to 24 h after surgery (group I 0±4 weeks, group II >4±26 weeks, group III >26±52 weeks, group IV >1±3 yr). Values
are percentages, or median (interquartile range). *P<0.001, group I vs groups II, III and IV; P=0.011 group II vs IV (c2-test). ²P<0.001 group I vs groups II,
III and IV (ANOVA). ³Excluding the loading dose of 100 mg kg±1
Group I Group II Group III Group IV
(n=63) (n=65) (n=30) (n=39)
*Patients with extra morphine (%) 38 91 87 72
² ³Morphine requirement (mg kg±1 h±1) 10.0 (10.0±10.7) 12.3 (10.6±16.6) 11.9 (10.4±15.3) 10.9 (10.0±14.3)
Fig 1 Percentages of patients in the four age groups (I 0±4 weeks, II
>4±26 weeks, III >26±52 weeks, IV >1±3 yr) needing additional
morphine during the ®rst 24 h after surgery.
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IM at 6, 12 and 24 h after surgery. Table 5 gives the ratios of
morphine and its metabolites at 24 h after surgery, and the
signi®cant differences between age groups. The M6G/M
ratio showed signi®cant differences between age groups but
not between the different treatments. The M6G/M ratio was
lower in group I than in all other groups. Neither age nor
treatment at any time point had any signi®cant effect on the
M6G/M3G ratio (Table 5).
Eleven spontaneous breathing patients (8 in the IM group,
3 in the CM group) developed postoperative respiratory
insuf®ciency; seven of them required intubation (5 in the IM
group, 2 in the CM group). Details of age, treatment,
surgical procedure, requirement of morphine and compli-
cations are given in Table 6.
Table 7 gives an overview of studies reporting require-
ments and plasma concentrations of morphine after non-
cardiac surgery, including the present data.24±26
Discussion
In this clinical study we investigated (i) the effects of
various variables on the morphine dose required in infants,
and (ii) the age-related changes in morphine and metabolite
concentration. Age was the most important factor differen-
tiating dose requirements between neonates and infants
older than 4 weeks. In a recent meta-analysis, a continuous
infusion rate of 7 mg kg±1 h±1 was calculated for term
neonates, assuming a desired steady-state plasma concen-
tration of 15 ng ml±1 for all ages.27 Neonates in our current
study received higher infusion rates and the concentrations
are proportionally similar. Because more than 60% of the
neonates had adequate analgesia with the minimal dose of
10 mg kg±1 h±1 (median concentration 22 ng ml±1), it is likely
that a lower dose of morphine would have suf®ced for the
neonates. Signi®cantly more morphine was used in the older
children, with requirements ranging from (median) 10.9 to
12.3 mg kg±1 h±1. Even with the additional morphine, the
required dose was lower than the recommended dosage of
20 mg kg±1 h±1.27±31 Remarkably, of the age groups older
than 4 weeks, children aged 1±3 yr needed the lowest
dosage of morphine (NS). They also had the lowest plasma
concentrations of morphine, which suggests that their
clearance was the highest.
Because concentration is directly proportional to dose, we
need to determine clearance in order to predict dose. The
wide range of neonatal plasma concentrations reported in
the literature was as expected, given the variability in
interindividual clearance (Table 7). In our study, plasma
concentrations of morphine in neonates (n=63) provided
adequate analgesia between 15.4 (trough) and 22 ng ml±1,
and, in infants older than 4 weeks (n=134), between 1.0 and
7.5 ng ml±1. These low plasma concentrations of morphine
apparently produced effective analgesia, as evidenced by
the low postoperative CS and VAS scores. It seems that
plasma concentrations as high as 15 ng ml±1 are not
necessary for adequate postoperative analgesia in infants >4
weeks of age. Although at the time of surgery all patients
had been without morphine therapy for more than 6 h,
plasma morphine was still detectable in ®ve neonates. This
indicates that clearance in this age group is low (approxi-
Table 4 Plasma concentrations (ng ml±1) of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) at 6, 12 and 24 h after surgery,
according to age (group I 0±4 weeks, group II >4±26 weeks, group III >26±52 weeks, group IV >1±3 yr) and treatment group. Data are median
(interquartile range). *Age group I higher than all other age groups (CM and IM) (P<0.001); ²Group II higher than IV (CM and IM) (P<0.001); **CM higher
than IM in all age groups (P<0.007); ³Group I higher than groups III and IV (CM and IM) (P<0.003) (ANOVA)
Time
after
Group I Group II Group III Group IV
surgery
(h)
CM n IM n CM n IM n CM n IM n CM n IM n
Morphine 6 25.0*
(14.3±32.0)
29 16.5*
(10.7±23.8)
28 8.5
(5.0±10.9)
28 5.7
(1.8±14.9)
27 8.6
(4.7±20.0)
14 2.9
(1.0±6.0)
14 5.2
(4.2±6.5)
18 1.0
(1.0±2.5)
17
12 23.0*
(12.0±31.0)
29 15.7*
(9.6±22.8)
28 7.9²
(5.5±12.3)
28 7.6²
(2.0±17.8)
25 5.6
(4.7±10.0)
15 1.1
(1.0±12.7)
13 4.9
(3.8±5.7)
16 1.7
(1.0±5.0)
18
24 22.0*
(15.1±29.5)
29 15.4*
(9.9±19.1)
25 7.4²
(5.3±13.4)
27 7.5²
(1.1±22.9)
24 6.4
(4.2±9.0)
15 1.0
(1.0±3.8)
13 4.8
(3.7±5.6)
17 2.3
(1.0±7.9)
17
M3G 6** 106.0³
(63.0±151.0)
19 73.0³
(39.3±87.8)
12 75.0²
(53.0±123.8)
26 67.5²
(40.0±101.5)
26 77.0
(52.5±116.5)
13 42.0
(22.1±75.8)
14 43.0
(31.0±61.0)
18 30.0
(16.7±55.0)
17
12 105.0*
(64.0±126.0)
19 73.5*
(48.0±123.8)
12 77.0²
(46.3±112.0)
26 58.0²
(28.0±77.0)
23 56.0
(40.3±87.5)
14 26.0
(22.5±54.0)
13 34.0
(23.0±57.0)
16 26.5
(21.3±80.3)
18
24 90.0*
(67.0±116.0)
19 79.0*
(46.0±131.0)
11 54.5²
(34.8±102.8)
26 45.0²
(30.5±69.0)
24 46.0
(38.3±71.8)
14 31.0
(19.8±37.5)
13 39.0
(28.5±51.0)
17 39.0
(18.3±69.0)
17
M6G 6 17.0*
(12.8±23.5)
29 12.2*
(8.9±16.0)
29 11.8²
(8.3±21.0)
29 8.8²
(6.0±14.7)
30 12.6
(7.8±17.1)
14 5.2
(3.7±11.1)
14 6.9
(4.5±8.8)
17 3.2
(2.1±6.1)
17
12 18.6*
(14.5±21.6)
29 14.6*
(10.5±19.7)
29 12.6²
(7.9±16.4)
29 10.8²
(4.4±16.6)
27 7.8
(5.9±12.1)
15 4.9
(3.7±7.0)
13 6.2
(4.5±8.1)
15 4.9
(2.9±9.4)
17
24 16.0*
(12.6±21.6)
29 13.2*
(10.3±19.0)
26 13.4²
(7.0±17.5)
27 7.1²
(4.5±12.5)
27 7.6
(6.1±10.9)
15 6.0
(3.6±6.6)
13 6.8
(4.8±10.6)
16 5.5
(2.8±10.7)
16
CM=continuous morphine; IM=intermittent morphine.
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mately 9 ml kg±1 min±1).9 Plasma morphine concentrations
were signi®cantly dependent on age, bearing in mind that
patients with renal impairment were not included.
Differences between treatment groups were only found at
6 h after surgery. Extra morphine dosages, given by nurses
on the basis of observational pain scores, resulted in similar
plasma concentrations in CM and IM from 12 h after
surgery. In the CM group, median concentrations decreased
from 7.4 to 6.4 to 4.8 ng ml±1 with increasing age in groups
II, III and IV. These data are consistent with an increase in
plasma clearance over the age range investigated.
Plasma concentrations of morphine that should produce
effective analgesia in neonates and older children have been
reported to range from 3.8 (SD 2.5) to 125 (9) ng ml±1.26 32±34
This wide range results from the various pain stimuli or
sedation end-points, differences in pain perception and pain
assessment, and variations in the children's clinical state
(severe illness, mechanical ventilation, needing sedation or
analgesia, tolerance, etc.). As reported earlier, the relation
between morphine requirement and plasma concentrations
is also dependent on the type of surgery, which leads to
different results after cardiac or non-cardiac surgery.6 34
Morphine is mainly metabolized in the liver into M3G
and M6G by uridine diphosphate glucuronyltransferase
(UDG2B7). The kidneys excrete these metabolites, as well
as a portion of the unchanged morphine. Developmental
maturation, associated with increasing renal clearance and
decreasing drug half-life, starts in the early neonatal period
and goes on for 2 yr. Using the three-quarters power model,
adult levels of clearance were reached at an earlier age (2±6
months).35
High morphine plasma concentrations and low M3G/M
and M6G/M ratios, as were found in the neonates, might
indicate a low glucuronidation capability. However, from
12 h after surgery, the highest plasma concentrations of
M3G and M6G were found in the neonates, showing that
they were able to glucuronidate morphine. Nevertheless,
hepatic induction of these enzyme systems cannot be ruled
out. The high plasma concentrations of morphine metabo-
lites in the neonates were the result of low renal clearance,
which was con®rmed by the signi®cant correlation between
serum creatinine and M6G in this age group. The decreased
clearance of morphine explains its increased analgesic
effect in neonates, contributed to by the active metabolite
M6G. While the M3G/M and M6G/M ratios increased with
age, indicating improved morphine metabolism, the M3G
and M6G plasma concentrations decreased with age,
indicating improved renal excretion, as reported in other
studies as well.7 34 36 37
In the present study, plasma concentrations of morphine
and morphine metabolites were not only signi®cantly
different between neonates (group I) and the older children
(groups II, III and IV), but also between infants aged 4±26
weeks (group II, median age 3 months) and 1±3 yr (group
IV, median age 20 months). The major changes in morphine
metabolism and elimination apparently take place in the ®rst
3 months after birth, and only minor differences in morphine
clearance are found after that age. The development of the
glucuronidation capability and the renal function might
have resulted in lower plasma concentrations of morphine in
the older children. Clinical effects, however, may be more
dependent on the concentrations in brain tissue, receptor
characteristics14 and other factors.
Fig 2 (A) Morphine, (B) morphine-3-glucuronide (M3G) and (C)
morphine-6-glucuronide (M6G) plasma concentrations (median) in the
four age groups (I 0±4 weeks, II >4±26 weeks, III >26±52 weeks, IV
>1±3 yr) at 6, 12 and 24 h after surgery. CM=continuous morphine,
IM=intermittent morphine.
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Reported correlations between metabolite/morphine
ratios and gestational age or birth weight are controversial.
M3G/M and M6G/M ratios increased with increasing birth
weight37 38 and gestational age38 (glucuronidation capabil-
ity increases), which was not found by Barrett and
colleagues.39 The disparity in plasma morphine glucuronide
ratios between the different studies could be a result of the
varying number of patients in the individual studies,
differences in gestational age and study age, in detection
limits of metabolites, and in the duration of morphine
infusions and the time of sampling. Because M3G and M6G
have long half-lives in neonates39 (impaired renal function),
it is suggestive that in neonates the M6G/M and M3G/M
ratios are increasing with increased periods of morphine
infusion.
In a review examining the effects of age, renal impair-
ment and route of administration on morphine metabolism,
Faura and colleagues7 reported a consistently high correl-
ation between M6G and M3G, with a ratio of about 15% in
neonates and children, as in adults. Across all studies, the
range of the ratios of metabolites to morphine was wide.
However, there was almost complete overlap between
children (>1 month) and adults, but neonates (<1 month)
had discernibly lower ratios for both metabolites. Although
Table 5 Ratios of metabolites (morphine-3-glucuronide, M3G; morphine-6-glucuronide, M6G) and morphine (M) 24 h after surgery (group I 0±4 weeks,
group II >4±26 weeks, group III >26±52 weeks, group IV >1±3 yr). *P<0.003 group I vs groups III and IV; P=0.03 group I vs group II (CM and IM)
(ANOVA). Values are median (interquartile range)
Group I Group II Group III Group IV
CM IM n CM IM n CM IM n CM IM n
M3G/M
ratio
5.2
(2.9±11.6)
7.0
(3.0±11.9)
28 8.6
(7.8±10.3)
9.6
(2.4±20.0)
47 8.0
(5.5±14.5)
15.7
(7.4±27.5)
27 9.1
(5.0±11.0)
16.7
(6.1±27.6)
34
M6G/M
ratio
0.8*
(0.5±1.7)
1.1
(0.7±1.5)
52 1.5
(1.2±2.1)
1.9
(0.5±3.8)
50 1.5
(0.9±2.3)
3.4
(1.1±5.9)
28 1.4
(1.0±2.1)
2.5
(1.3±4.6)
32
M6G/M3G
ratio
0.22
(0.16±0.23)
0.17
(0.13±0.25)
30 0.18
(0.15±0.23)
0.17
(0.15±0.21)
49 0.18
(0.15±0.19)
0.19
(0.16±0.24)
27 0.18
(0.16±0.22)
0.16
(0.14±0.19)
32
CM=continuous morphine, IM=intermittent morphine.
Table 6 Data of 11 patients with respiratory insuf®ciency during the ®rst 24 h after surgery
Age
(days)
CM/IM Diagnosis Complications Extra
morphine
(Y/N)
Mean dose
morphine
(mg kg±1 h±1)
Re-intubation?
Y/N
Hr after
surgery
Comments
1 IM Exstrophy of the
bladder
Apnoea N 10 Y 6 Bryant's traction
1 IM Jejunal atresia Apnoea N 10 Y <4 30 min after
morphine bolus
2 IM Tracheo-oesophageal
atresia
Respiratory
obstruction
N 10 Y 21 Failed extubation
3 IM Tracheo-oesophageal
atresia
Respiratory
obstruction
N 10 Y 15 Failed extubation
4 IM Duodenal atresia PCO2 increased
(8.9 and 8.3 kPa at 6
and 12 h after surgery)
N 10 N Down's syndrome
54 CM Neuroblastoma Apnoea Y 10.2 Y 6
61 CM Ileus Apnoea Y 22.2 Y 6 High pain scores;
100 mg kg±1extra
morphine in 3 h
78 IM Rehbein resection PCO2 increased
(8.4 kPa at 6 h
after surgery)
Y 10.7 N
90 IM Nissen fundoplication Inspiratory and
expiratory stridor
2 h after surgery
Y 10.4 Y < 4
102 IM Bilobectomy PCO2 increased
(7.4 and 7.5 kPa at
6 and 12 h after surgery)
Y 11.7 N Pneumonia
831 CM Neuroblastoma Apnoea N 10 N 12 Morphine stopped at
12 h after surgery
CM=continuous morphine, IM=intermittent morphine, M=morphine.
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the number of neonates and children was small compared
with that of adults (49, 90 and 1073, respectively), the M3G/
M6G ratio remained constant in all subgroups (including
neonates, children and adults, patients with renal impair-
ment, and different routes of administration).
In the present study, neonates differed signi®cantly from
the older children in median M6G/M ratio (P=0.003) but
there were no signi®cant differences between the three older
age groups. The M6G/M3G ratio at 24 h after i.v. morphine
was not signi®cantly different between the four age groups
(0±3 yr).
Although the data are dif®cult to compare (median vs
mean weighted values7), both studies result in similar
conclusions: (i) neonates differ signi®cantly from older
patients (children and adults, respectively), having an
immature morphine metabolism; (ii) children older than 4
weeks metabolize morphine like older children, as presented
in our study, and like adults;7 and (iii) the M6G/M3G ratio
remains constant at all ages.
Hartley and colleagues37 reported decreasing M6G/M3G
plasma ratios, although not signi®cantly, with increasing
birth weight. This might suggest a differential development
of enzymes (UGT2B7) for the formation of M3G and M6G.
Recently, it was shown that UGT2B7 is responsible for the
glucuronidation of morphine and is capable of catalysing the
glucuronidation of both the 3- and 6-hydroxyl moieties on
these molecules.40 41 However, polymorphism in the coding
sequence, as well as in the 5¢-¯anking region, may affect the
rate of morphine glucuronidation and can result in individ-
ual differences.42
The SSS was developed as a measure of the severity of
surgical stress.18 Although in the present study the scores
did not differ signi®cantly between age or treatment groups,
multiple regression analysis showed that they signi®cantly
in¯uenced the dosage of morphine required. In the absence
of other methods that can directly measure postoperative
pain across different age groups, the SSS may help to assess
the need for postoperative morphine.
Eight of the 11 children who showed respiratory insuf-
®ciency were in the IM treatment group. In most of these
patients respiratory depression could not be attributed to the
morphine therapy but had to be considered as a complica-
tion of their surgical operation.
In conclusion, age is the most important factor in
morphine requirement and morphine metabolism. In our
previous study investigating the effect of CM and IM on
surgical stress responses in the same patient population,
infants aged 1±3 yr in the IM group showed greater stress
than those in the CM group.17 Combining the results of both
studies, we conclude that morphine given intermittently
does not provide any clinical advantages and that a
continuous morphine infusion is probably safer in neonates
and more effective in older infants. By stratifying for age
and carefully monitoring the children's behaviour, we were
able to give more precise dosages for postoperative
morphine after major non-cardiac surgery. We agree with
the recommended dosage for continuous morphine infu-
sions of 7 mg kg±1 h±1 in full-term neonates.27 However, we
would advise starting with an infusion rate of 10 mg kg±1 h±1
in infants >4 weeks of age. Differences in developmental
maturation between neonates and infants indicate the need
for individual drug dosages. Increase of the infusion rates
should only be based on pain scoring by trained nurses, in
order to prevent overdosing.
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